EA200201186A1 - УСТОЙЧИВЫЕ КОМПОЗИЦИИ 6-ГИДРОКСИ-3-(4-[2-(ПИПЕРИДИН-1-ИЛ)ЭТОКСИ]ФЕНОКСИ)-2-(4-МЕТОКСИФЕНИЛ) БЕНЗО[b] ТИОФЕНА И ЕГО СОЛЕЙ - Google Patents

УСТОЙЧИВЫЕ КОМПОЗИЦИИ 6-ГИДРОКСИ-3-(4-[2-(ПИПЕРИДИН-1-ИЛ)ЭТОКСИ]ФЕНОКСИ)-2-(4-МЕТОКСИФЕНИЛ) БЕНЗО[b] ТИОФЕНА И ЕГО СОЛЕЙ

Info

Publication number
EA200201186A1
EA200201186A1 EA200201186A EA200201186A EA200201186A1 EA 200201186 A1 EA200201186 A1 EA 200201186A1 EA 200201186 A EA200201186 A EA 200201186A EA 200201186 A EA200201186 A EA 200201186A EA 200201186 A1 EA200201186 A1 EA 200201186A1
Authority
EA
Eurasian Patent Office
Prior art keywords
piperidin
benzo
methoxyphenyl
phenoxy
hydroxy
Prior art date
Application number
EA200201186A
Other languages
English (en)
Other versions
EA004871B1 (ru
Inventor
Фадия Наджар Башор
Керри Джон Хартоэр
Майкл Дин Миннетт
Юджин Кларк Рикард
Черил Энн Тингл
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA200201186A1 publication Critical patent/EA200201186A1/ru
Publication of EA004871B1 publication Critical patent/EA004871B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к фармацевтическим композициям, содержащим 6-гидрокси-3-(4-[2-(пиперидин-1-ил)этокси]фенокси)-2-(4-метоксифенил)бензо[b]тиофен или его соль, устойчивым к окислению или другим формам разложения, за счет включения стабилизирующего агента, выбранного из метионина, ацетилцистеина, цистеина и его солей.
EA200201186A 2000-05-08 2001-04-30 УСТОЙЧИВЫЕ КОМПОЗИЦИИ 6-ГИДРОКСИ-3-(4-[2-(ПИПЕРИДИН-1-ИЛ)ЭТОКСИ]ФЕНОКСИ)-2-(4-МЕТОКСИФЕНИЛ) БЕНЗО[b] ТИОФЕНА И ЕГО СОЛЕЙ EA004871B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20323500P 2000-05-08 2000-05-08
PCT/US2001/011736 WO2001085147A2 (en) 2000-05-08 2001-04-30 STABILIZED FORMULATIONS OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL) BENZO[b]THIOPHENE AND SALTS THEREOF

Publications (2)

Publication Number Publication Date
EA200201186A1 true EA200201186A1 (ru) 2003-08-28
EA004871B1 EA004871B1 (ru) 2004-08-26

Family

ID=22753086

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200201186A EA004871B1 (ru) 2000-05-08 2001-04-30 УСТОЙЧИВЫЕ КОМПОЗИЦИИ 6-ГИДРОКСИ-3-(4-[2-(ПИПЕРИДИН-1-ИЛ)ЭТОКСИ]ФЕНОКСИ)-2-(4-МЕТОКСИФЕНИЛ) БЕНЗО[b] ТИОФЕНА И ЕГО СОЛЕЙ

Country Status (31)

Country Link
EP (1) EP1357903B1 (ru)
JP (1) JP2003535827A (ru)
KR (1) KR100806992B1 (ru)
CN (1) CN1283250C (ru)
AR (1) AR028401A1 (ru)
AT (1) ATE348605T1 (ru)
AU (2) AU2001255310C1 (ru)
BR (1) BR0110620A (ru)
CA (2) CA2691739A1 (ru)
CZ (1) CZ20023651A3 (ru)
DE (1) DE60125416T2 (ru)
DZ (1) DZ3376A1 (ru)
EA (1) EA004871B1 (ru)
EC (1) ECSP014066A (ru)
EG (1) EG24223A (ru)
ES (1) ES2276784T3 (ru)
HK (1) HK1061349A1 (ru)
HR (1) HRP20020883A2 (ru)
HU (1) HUP0302190A3 (ru)
IL (2) IL152699A0 (ru)
MX (1) MXPA02010923A (ru)
NO (1) NO20025219L (ru)
NZ (1) NZ521393A (ru)
PE (1) PE20011255A1 (ru)
PL (1) PL365472A1 (ru)
SK (1) SK286346B6 (ru)
SV (1) SV2002000435A (ru)
TW (1) TWI225787B (ru)
UA (1) UA77941C2 (ru)
WO (1) WO2001085147A2 (ru)
ZA (1) ZA200207651B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610706B1 (en) 1999-07-29 2003-08-26 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
US6653479B1 (en) 1999-07-29 2003-11-25 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophene hydrochloride
CA2539799A1 (en) * 2003-09-22 2005-03-31 Nisshin Kyorin Pharmaceutical Co., Ltd. 5-aminosalicylic acid solid preparation improved in discoloration and method of storing the same
WO2016024369A1 (ja) * 2014-08-13 2016-02-18 テバ製薬株式会社 がん治療用医薬組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL182493B1 (pl) * 1995-02-28 2002-01-31 Lilly Co Eli Nowe pochodne benzotiofenu, nowe związki pośrednie i sposób wytwarzania nowych pochodnych benzotiofenu oraz środek farmaceutyczny
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
CY2344B1 (en) * 1999-07-29 2004-06-04 Lilly Co Eli A novel crystalline form of 6-hydroxy-3-(4-(2-(piperidin-1-yl) ethoxy) phenoxy)-2-(4-methoxyphenyl) benzo (b) thiphene hydrochloride.
DE60005693T2 (de) * 1999-07-29 2004-07-29 Eli Lilly And Co., Indianapolis Eine kristalline form von 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophen-hydrochlorid
EP1204656A2 (en) * 1999-07-29 2002-05-15 Eli Lilly And Company A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy] phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene hydrochloride

Also Published As

Publication number Publication date
UA77941C2 (en) 2007-02-15
ES2276784T3 (es) 2007-07-01
WO2001085147A3 (en) 2003-08-28
JP2003535827A (ja) 2003-12-02
DE60125416T2 (de) 2007-09-27
NO20025219D0 (no) 2002-10-31
HUP0302190A2 (hu) 2003-10-28
SV2002000435A (es) 2002-10-24
NO20025219L (no) 2002-10-31
PL365472A1 (en) 2005-01-10
ZA200207651B (en) 2003-12-23
AU2001255310B8 (en) 2005-03-10
DE60125416D1 (de) 2007-02-01
WO2001085147A2 (en) 2001-11-15
DZ3376A1 (fr) 2001-11-15
EP1357903A2 (en) 2003-11-05
KR100806992B1 (ko) 2008-02-25
ATE348605T1 (de) 2007-01-15
SK286346B6 (en) 2008-07-07
SK15652002A3 (sk) 2003-04-01
IL152699A0 (en) 2003-06-24
HK1061349A1 (en) 2004-09-17
EA004871B1 (ru) 2004-08-26
CA2691739A1 (en) 2001-11-15
TWI225787B (en) 2005-01-01
EP1357903B1 (en) 2006-12-20
PE20011255A1 (es) 2001-12-11
MXPA02010923A (es) 2003-03-27
HUP0302190A3 (en) 2009-03-30
HRP20020883A2 (en) 2005-02-28
AU5531001A (en) 2001-11-20
AU2001255310B2 (en) 2005-03-03
KR20030009477A (ko) 2003-01-29
NZ521393A (en) 2004-08-27
BR0110620A (pt) 2003-04-01
ECSP014066A (es) 2002-02-25
CN1545413A (zh) 2004-11-10
CZ20023651A3 (cs) 2003-02-12
EG24223A (en) 2008-11-10
CN1283250C (zh) 2006-11-08
AU2001255310C1 (en) 2006-03-09
CA2408563A1 (en) 2001-11-15
AR028401A1 (es) 2003-05-07
IL152699A (en) 2009-09-01

Similar Documents

Publication Publication Date Title
CY1107512T1 (el) Νεες υποκατεστημενες με βενζιμιδαζολιο μορφες δοσολογιας και μεθοδος για τη χρηση τους
UY27320A1 (es) Nuevas composiciones farmacéuticas
DK0759919T3 (da) Azolidindioner som antihyperglykæmiske midler
AR028706A1 (es) Tiazina oxazolidinona
DE68913930D1 (de) Serotonin- und Norepinephrin-Aufnahme-Inhibitoren.
HRP20020198B1 (en) Moxifloxacin formulation containing common salt
ATE260275T1 (de) Substituierte thien-3-yl- sulfonylamino(thio)carbonyl-triazolin(thi)one
DK1078923T3 (da) Fremgangsmåde til fremstilling af benzothiophenderivater
HRP20080330T3 (en) Antitumoral compounds based on kahalalide f
MY135954A (en) Crystalline form of (s)-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) phenyl] propanoic acid
AR044864A1 (es) Composiciones orales antiplaca acuosas estables
ATE453389T1 (de) Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen
ID24846A (id) Turunan-turunan bifenilamidina
EA200201186A1 (ru) УСТОЙЧИВЫЕ КОМПОЗИЦИИ 6-ГИДРОКСИ-3-(4-[2-(ПИПЕРИДИН-1-ИЛ)ЭТОКСИ]ФЕНОКСИ)-2-(4-МЕТОКСИФЕНИЛ) БЕНЗО[b] ТИОФЕНА И ЕГО СОЛЕЙ
BR9812982A (pt) Agente anti-reumático
FI20001721A (fi) 6-hydroksi-3-(4-(/2-(piperidin-1-yyli)etoksi)fenoksi)-2-(4-metoksifenyyli)bentso(b)tiofeenihydrokloridin uusin kiteinen muoto
DK1174131T3 (da) Anvendelse af et middel til forbedring af astrocytfunktion til behandling af Parkinsons sygdom
EP1757291A3 (en) Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-YL)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof
ATE359350T1 (de) Verdickte wässrige zusammensetzungen
DK1411956T3 (da) Anvendelse af oversulfaterede polysaccharider som inhibitorer af HIV
BR0107204A (pt) Inibidores da angiogênese de hidrazida e alcoxiamida
HUP0100999A2 (hu) Citosztatikus szerek
HRP20030653B1 (en) Novel benzoylguanidine salt
DK1312608T3 (da) Discodermolid-analoge samt deres farmaceutiske anvendelse
ES2150392B1 (es) "composiciones parenterales a base de calcitonina".

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU